| Literature DB >> 35011753 |
Polina I Kuznetsova1, Anton A Raskurazhev1, Rodion N Konovalov2, Marina V Krotenkova2, Andrey O Chechetkin3, Olga V Lagoda1, Anait L Melikhyan4, Marine M Tanashyan1.
Abstract
BACKGROUNDS ANDEntities:
Keywords: Philadelphia chromosome-negative myeloproliferative disorders; covert brain infarcts; endothelial dysfunction; hematology
Year: 2021 PMID: 35011753 PMCID: PMC8745571 DOI: 10.3390/jcm11010013
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241
Figure 1Patient selection flowchart.
Figure 2Covert brain infarcts in patients of the study group (MRI). (A,B)–DWI; (C,D)–T2 FLAIR.
The prevalence of the main risk factors for stroke.
| Essential Thrombocytemia | Polycytemia Vera | Primary Myelofibrosis | MPD (All) |
| |
|---|---|---|---|---|---|
| Number (%) | 38 (36.9) | 42 (40.77) | 23 (22.33) | 103 (100) | N/A |
| Age (median (1st quartile; 3rd quartile) | 40 (30.5; 52.5) | 51 (41.2; 55) | 46 (33.5; 53) | 47 (35; 54) | 0.09 |
| Female (%) | 29 (76.3) | 22 (52.4) | 18 (78.3) | 69 (67) | 0.03 |
| Arterial hypertenison (%) | 9 (23.7) | 14 (33.3) | 7 (30.4) | 30 (29.1) | 0.63 |
| Diabetes mellitus type 2 (%) | 1 (2.6) | 1 (2.4) | 0 (0) | 2 (1.9) | 0.74 |
| Myocardial infarction (%) | 2 (5.3) | 3 (7.1) | 1 (4.3) | 6 (5.8) | 0.88 |
| Venous thromboses (%) | 7 (18.4) | 6 (14.3) | 1 (4.3) | 14 (13.6) | 0.29 |
| Risk category | |||||
| Low (%) | 12 (31.6) | 23 (54.8) | 20 (87.0) | 55 (53.4) | <0.01 |
| Intermediate (%) | 18 (47.4) | 12 (28.6) | 3 (13.0) | 33 (32.0) | 0.02 |
| High (%) | 8 (21.0) | 7 (16.6) | - | 15 (14.6) | 0.83 |
| JAK V6717F carrier (%) | 22 (57.9) | 40 (95.2) | 13 (56.5) | 75 (72.8) | <0.01 |
| Carotid atherosclerosis (%) | 8 (21.1) | 17 (40.5) | 6 (26.1) | 31 (30.1) | 0.15 |
| Antiplatelet therapy (%) | 32 (84.2) | 37 (88.1) | 20 (86.9) | 89 (86.4) | 0.88 |
| Headache (%) | 25 (65.8) | 25 (59.5) | 18 (78.3) | 68 (66) | 0.31 |
Covert brain infarcts compared to patients without MRI ischemic lesions.
| CBIs ( | MRI Lesion-Free ( |
| |
|---|---|---|---|
| Age | 50 (43; 57) | 36 (29; 48) | <0.01 |
| Arterial hypertension (%) | 3 (18.75) | 10 (21.3) | 0.83 |
| Atherosclerosis (%) | 6 (37.5) | 7 (14.9) | 0.12 |
| Venous thromboses (%) | 3 (18.75) | 5 (10.6) | 0.68 |
| JAK carriers | 13 (81.25) | 31 (65.9) | 0.40 |
| Female (%) | 9 (56.25) | 35 (74.5) | 0.29 |
| Male (%) | 7 (43.75) | 12 (25.5) | 0.29 |
| JAK2 (allele burden) | 14.5 (5.7; 34.0) | 6 (0; 16.5) | 0.08 |
| Headache (%) | 9 (56.25) | 32 (68.1) | 0.58 |
| Flow-mediated vasodilation | 5.5 (4.0; 8.0) | 11 (7;13) | <0.01 |
| Hemoglobin, g/L | 151 (140.5; 162) | 135 (121; 144) | 0.01 |
| Erythrocytes | 4.75(4.2; 5.0) | 4.8 (4.2; 5.4) | 0.75 |
| Thrombocytes | 433 (268; 517) | 552 (465; 619.5) | <0.05 |
| Leukocytes | 7.4 (5.7; 8.9) | 7.1 (5.9; 8.8) | 0.84 |
| ESR * | 6 (5; 10.5) | 5 (2.5; 10.5) | 0.51 |
| Hydroxyurea (%) | 13 (81.3) | 25 (53.2) | 0.09 |
* Erythrocyte sedimentation rate.
Figure 3Flow-mediated dilation (FMD) rates. MRI lesion-free vs. CBIs.
Multivariable logistic regression analysis.
| B | S.E. | O.R. | C.I (95%) |
| ||
|---|---|---|---|---|---|---|
| (Intercept) | −1.88 | 9.47 | 7 × 10−9 | 1 × 10−18 | 0.06 | 0.04 |
| Age | 0.12 | 0.08 | 1.12 | 0.97 | 1.38 | 0.16 |
| AH+ | −2.78 | 1.79 | 0.06 | 0.0005 | 1.27 | 0.12 |
| AS | 2.20 | 2.14 | 9.15 | 0.35 | 3 × 103 | 0.30 |
| VT | 1.70 | 2.67 | 5.5 | 0.11 | 1 × 103 | 0.45 |
| JAK2 carrier | 1.81 | 2.60 | 6.08 | 0.08 | 5.7 × 103 | 0.49 |
| Male | −0.56 | 1.21 | 0.57 | 0.04 | 5.74 | 0.64 |
| JAK2 (allele burden) | −0.006 | 0.04 | 0.99 | 0.91 | 1.07 | 0.86 |
| Headache | −3.17 | 1.62 | 0.04 | 0.0006 | 0.60 | 0.05 |
| FMD | −0.35 | 0.15 | 0.71 | 0.49 | 0.90 | 0.02 |
| Hemoglobin | 0.19 | 0.09 | 1.21 | 1.06 | 1.55 | 0.03 |
| Erythrocytes | −3.12 | 1.71 | 0.04 | 0.0004 | 0.53 | 0.06 |
| Platelets | 0.0002 | 0.004 | 1.00 | 0.99 | 1.01 | 0.96 |
| Leukocytes | 0.23 | 0.37 | 1.26 | 0.61 | 2.80 | 0.53 |
| ESR | 0.02 | 0.14 | 1.03 | 0.75 | 1.37 | 0.86 |
| Hydroxyurea | 1.95 | 1.49 | 7.01 | 0.52 | 2.3 × 102 | 0.19 |